GANX
GANX
NASDAQ · Biotechnology

Gain Therapeutics Inc

$1.75
+0.13 (+8.02%)
As of Feb 8, 2:16 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 11.43M 10.74M 10.31M
Net Income -2,402,162 -1,945,366 -2,138,218
EPS
Profit Margin -21.0% -18.1% -20.7%
Rev Growth +22.4% -6.0% +21.1%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 28.77M 29.36M 24.76M
Total Equity 26.08M 22.63M 21.54M
D/E Ratio 1.10 1.30 1.15
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -3,961,862 -3,629,854 -3,514,676
Free Cash Flow -2,281,552 -2,429,555 -1,597,015